Takeda consolidates business in Singapore, opening new office

25 February 2015

Japanese drug major Takeda (TYO: 4502) has opened its new office in Biopolis, Singapore. The space will host its emerging market business unit headquarters, the Takeda development center for Asia and its vaccine business unit.

It aims to enhance efficiencies and enable Takeda to better understand and meet the needs of Asian customers by consolidating and streamlining Singapore operations.

The vaccine business unit based in Singapore hosts a laboratory for analytics and development of vaccines to protect against infectious diseases in the region. The dengue fever vaccine currently in development will soon enter Phase III trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK